Adagio Medical (ADGM) Projected to Post Quarterly Earnings on Wednesday

Adagio Medical (NASDAQ:ADGM) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.2467) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Adagio Medical (NASDAQ:ADGM) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.03). On average, analysts expect Adagio Medical to post ($1.25) EPS for the current fiscal year and ($1.75) EPS for the next fiscal year.

Adagio Medical Price Performance

ADGM opened at $0.09 on Wednesday. Adagio Medical has a 1 year low of $0.08 and a 1 year high of $1.69. The company has a debt-to-equity ratio of 4.00, a current ratio of 1.41 and a quick ratio of 1.15. The company has a market capitalization of $2.37 million, a price-to-earnings ratio of -0.06 and a beta of 0.07. The firm’s fifty day moving average price is $0.29 and its two-hundred day moving average price is $0.74.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Adagio Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.50.

About Adagio Medical

Adagio Medical, Inc is a medical technology company focused on developing catheter-based treatments for cardiac arrhythmias, including atrial fibrillation. The company’s technology is designed to create continuous, transmural lesions in cardiac tissue to isolate abnormal electrical signals and help restore a normal heart rhythm.

Its lead platform is the Intelligent Continuous Lesion Ablation System (iCLAS), an ultra-low-temperature cryoablation system intended to treat atrial fibrillation and other heart rhythm disorders.